SeekingAlpha · Mar 5, 2026
CR
NASDAQ · CRMD
CorMedix Inc.
Healthcare · Biotechnology
$7.19
Down-$0.03 (-0.35%)
Updated Oct 5, 2026, 3:26 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 924.2M
- P/E ratio
- 5.48
- Dividend yield
- 0.00%
- 52-week range
- $6.14 – $9.09
- Volume
- 1.13M
- Avg. volume
- 2.73M
Price performance · CRMD
CRMD price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
CRMD closed at $7.19 after 19 trading sessions, down 12.10% for the selected period.
- Last close
- $7.19
- Period change
- -12.10%
- Period low
- $7.19
- Period high
- $8.18
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $7.45 | $7.45 | $7.165 | $7.19 | 1.13M |
| Oct 1, 2026 | $7.65 | $7.685 | $7.40 | $7.42 | 1.05M |
| Sep 30, 2026 | $7.95 | $7.95 | $7.66 | $7.70 | 948.36K |
| Sep 29, 2026 | $7.91 | $7.96 | $7.82 | $7.93 | 817.43K |
| Sep 28, 2026 | $7.772 | $7.90 | $7.772 | $7.89 | 485.28K |
| Sep 25, 2026 | $7.79 | $7.90 | $7.69 | $7.85 | 606.65K |
| Sep 24, 2026 | $7.70 | $7.785 | $7.62 | $7.77 | 946.58K |
| Sep 23, 2026 | $8.025 | $8.185 | $7.625 | $7.69 | 812.57K |
| Sep 22, 2026 | $7.83 | $7.83 | $7.69 | $7.78 | 788.93K |
| Sep 21, 2026 | $7.72 | $7.82 | $7.62 | $7.77 | 505.84K |
| Sep 18, 2026 | $7.65 | $7.79 | $7.62 | $7.72 | 1.81M |
| Sep 17, 2026 | $7.86 | $7.92 | $7.695 | $7.79 | 684.75K |
| Sep 16, 2026 | $7.78 | $7.87 | $7.72 | $7.82 | 664.71K |
| Sep 15, 2026 | $7.90 | $7.90 | $7.71 | $7.76 | 718.71K |
| Sep 14, 2026 | $7.83 | $7.945 | $7.748 | $7.89 | 920.27K |
| Sep 11, 2026 | $8.04 | $8.06 | $7.82 | $7.825 | 820.99K |
| Sep 10, 2026 | $8.11 | $8.12 | $7.92 | $7.96 | 857.26K |
| Sep 9, 2026 | $8.18 | $8.33 | $8.08 | $8.13 | 928.24K |
| Sep 8, 2026 | $8.28 | $8.37 | $8.11 | $8.18 | 1.1M |
Latest CRMD news
The latest Smart Investors Daily articles mentioning CRMD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CRMD research
Overview
Company profile and research snapshot.
Company profile
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $19.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | Outperform | — |
| Aug 14, 2026 | RBC Capital | Outperform | — |
| Jul 7, 2026 | RBC Capital | Outperform | — |
| Apr 28, 2026 | RBC Capital | Outperform | — |
| Apr 28, 2026 | Leerink Partners | Outperform | — |
News briefing
No generated briefing is available yet.
ChartMill · Mar 5, 2026
CorMedix Inc (NASDAQ:CRMD) Shares Drop on Q4 2025 Earnings Miss
CorMedix reports strong Q4 2025 revenue growth but misses EPS estimates, leading to a sharp pre-market stock decline.
Benzinga · Mar 5, 2026
CorMedix shares are trading lower after the company reported mixed Q4 financial results.
Benzinga · Mar 5, 2026
CORRECTION: Cormedix Affirms FY2026 Sales Guidance of $300.000M-$320.000M
Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $300.000 million-$320.000 million to $300.000 million-$320.000 million.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
